Neonatal alloimmune thrombocytopenia (NAIT) is a rare yet potentially life‐threatening condition caused by maternal sensitisation to fetal platelet antigens, most notably human platelet antigen 1a.

Biotech pressures exposed as big job losses are announced at Vor Bio, IGM Biosciences, Rallybio, Insitro, and Korro Bio ...

In neonates with sepsis, thrombocytopenia is a common hematologic abnormality that appears to be an early prognostic indicator of disease severity. It is known that severe fetal and neonatal ...

Stem cell therapy, artificial womb technology, and telehealth innovations are reshaping neonatal care and improving outcomes for infants affected by complex conditions, including fetal and neonatal ...

The study offers hope for the effective treatment of alloimmunisation. Another immunisation disorder in the fetus and newborn is fetal/neonatal alloimmune thrombocytopenia (FNAIT). The mother forms ...

A case of neonatal alloimmune thrombocytopenia (NAIT) secondary to human platelet antigen (HPA)-1a antibodies is reported. Additional multispecific HLA antibodies rendered volunteer donor platelet ...

U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021, fetal and neonatal alloimmune ...